CN103798808A - Nutrient formula and application thereof to food or medicine for reliving asthenopia - Google Patents
Nutrient formula and application thereof to food or medicine for reliving asthenopia Download PDFInfo
- Publication number
- CN103798808A CN103798808A CN201210460781.3A CN201210460781A CN103798808A CN 103798808 A CN103798808 A CN 103798808A CN 201210460781 A CN201210460781 A CN 201210460781A CN 103798808 A CN103798808 A CN 103798808A
- Authority
- CN
- China
- Prior art keywords
- formula
- zinc
- nutrients
- gram
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 35
- 235000013305 food Nutrition 0.000 title claims abstract description 12
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title claims abstract description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- 229960005375 lutein Drugs 0.000 claims abstract description 16
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 16
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 16
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 16
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 12
- 230000004438 eyesight Effects 0.000 claims abstract description 12
- 239000011701 zinc Substances 0.000 claims abstract description 12
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 12
- 235000016804 zinc Nutrition 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 10
- 239000011719 vitamin A Substances 0.000 claims abstract description 10
- 229940045997 vitamin a Drugs 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 208000002177 Cataract Diseases 0.000 claims abstract description 7
- 201000008525 senile cataract Diseases 0.000 claims abstract description 5
- 235000012680 lutein Nutrition 0.000 claims description 15
- 239000001656 lutein Substances 0.000 claims description 15
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 5
- 235000011478 zinc gluconate Nutrition 0.000 claims description 5
- 239000011670 zinc gluconate Substances 0.000 claims description 5
- 229960000306 zinc gluconate Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002398 materia medica Substances 0.000 claims description 4
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 4
- 235000006076 zinc citrate Nutrition 0.000 claims description 4
- 239000011746 zinc citrate Substances 0.000 claims description 4
- 229940068475 zinc citrate Drugs 0.000 claims description 4
- 150000003752 zinc compounds Chemical group 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000008210 xanthophylls Nutrition 0.000 abstract 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 abstract 1
- 230000006378 damage Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 210000000695 crystalline len Anatomy 0.000 description 5
- 230000004310 photopic vision Effects 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000002189 macula lutea Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- -1 luteole Chemical compound 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a nutrient formula for reliving asthenopia and particularly relates to a nutritional agent containing zeaxanthine, xanthophyll, vitamin A, vitamin C, vitamin E and zinc. The nutrient formula has the effects of anti-oxidization, asthenopia reliving and vision protection, and has the effects of preventing and reliving the progress of senile macular degeneration and cataract; the nutrient formula can be used for the fields of foods, health-care foods, medicines and the like.
Description
Technical field
The present invention relates to a kind of nutrients formula of alleviating asthenopia.
Background technology
Human eye's structure is very complicated, but different from its hetero-organization of human body, the tissue of eyes does not just upgrade after forming, such as the most cells in human body crystalline lens forms when the embryo, after formation, not the upgrading in life of people, therefore eyesight can fail with age.
When light is focused on by crystalline lens through after cornea, aqueous humor along pupil, the light of focusing drops on retina through vitreum, and the cell on retina is converted into nerve impulse by light energy and passes to brain by optic nerve and form image.Lenticular protein may be oxidized and damage, and with age and the damage of accumulation causes penetrability to reduce, finally can form cataract and may cause blind.Composition retina is that the cell of optic nerve tissue too can not mitosis, once these cells damages are permanent damages, can cause retinal degeneration, and then cause the accumulation of metabolism relic, finally causes with age visual impairment even blind.This with age growth crystalline lens, the final blind senile macular degeneration (age-related macular degeneration, AMD) that is called as of amphiblestroid decline deterioration.Also there is no effective treatment means for AMD at present, can only manage prevention and slow down AMD development.Research shows that active oxygen is the morbidity principal element that causes AMD, X.L.SHEN has studied the relation of Antioxidant Indexes and AMD in the blood in 100 Chinese Bloods, result shows that in AMD blood samples of patients, oxidation resistance is starkly lower than normal control people group, therefore the oxidation of reaching a conclusion is likely paathogenic factor (the The Journal of Nutrition of AMD, Health & Aging.Volume 16, Number 3,2012).The antioxidants such as replenishing vitamins C, vitamin E can delay development process (AREDS report no.8, the Arch Ophthalmol.2001 of AMD; 119:1417-36).
In the time that the light of different wave length enters eyes, first pass through cornea and lenticular filtration, cornea can scan all ultraviolet lights, and crystalline lens reflection stops ultraviolet ray to enter eyes, filters out ultraviolet light finally can arrive retina through crystalline lens.Cornea and lenticular UV scanning function may loss eyes structure, light drops on retina can damage some cells, the red wavelength of energy force rate that blue wavelength in visible ray stimulates retina cell to form free radical is eager to excel 100 times, and therefore blue light is the amphiblestroid main arch-criminal of damage.Macula lutea is gathered light receiver in retina, the nucleus of being responsible for visual acuity, contains abundant lutein and luteole in macula lutea, and the two has formed macular pigment.Macular pigment has antioxidation, the damage (Nutrition Reviews, Vol.63, No.2) of the radical pair light-receiving cell that prevention elevated oxygen level causes; Luteole and lutein filter blue light, in order to avoid blue light arrives macula lutea, can significantly alleviate retina oxygen pressure (Clinics in Dermatology (2009) 27,195-201).Human body cannot self synthesize lutein and luteole; must obtain by diet; if absorption lutein and luteole can not cause the various discomforts of eyes completely; even cause cataract and macular degeneration, therefore suitably supplement lutein, luteole, vitamin A and polyphenoils confrontation vision protection and there is very important effect.
Summary of the invention
The object of this invention is to provide a kind of formula of nutrient of alleviating asthenopia; in this formula, contain the antioxidant composition such as vitamin C, vitamin E, zinc; also contain the macular pigment such as lutein, luteole and eyes nutrient vitamin A; there is effect anti-oxidant, that alleviate kopiopia, vision protection, senile macular degeneration and cataract are had prevention and slowed down the pace, can be used for the fields such as food, health food, medicine.
For achieving the above object, the technical solution used in the present invention is as follows:
A kind of nutrients formula, in every 100 grams of nutrients formulas, the amount of active ingredient is: luteole: 0.15 ~ 7.5 gram; Lutein: 0.15 ~ 7.5 gram, vitamin C: 1 ~ 30 gram, vitamin E: 0.1 ~ 15 gram, vitamin A: 0.02 ~ 0.4 gram, zinc: 0.15 ~ 10 gram.
Surplus in nutrients formula except active ingredient is carrier or auxiliary material.
Described zinc is the zinc that is added into formula with zinc gluconate, zinc citrate or other zinc compound forms.
Described carrier or auxiliary material are acceptable carrier or auxiliary material on food or materia medica, and nutrients formula is made different formulations according to the carrier or the auxiliary material that add.
The application of described nutrients formula in food or the medicine of preparing alleviating asthenopia.
Nutrients formula is made different formulations according to the carrier or the auxiliary material that add, and carrier or auxiliary material are acceptable carrier or auxiliary material on food or materia medica.
Described nutrients formula is eyes nutrient, its have anti-oxidant, alleviate kopiopia, vision protection effect, the effect that senile macular degeneration and cataract are had prevention and slowed down the pace.
Zinc is the ionic zinc with the equivalent of zinc gluconate, zinc citrate or other zinc compound forms.
Nutrient formulation of the present invention uses separately or prepares into different formulations from other drug, as powder, pill, capsule, tablet, microcapsules, soft capsule, suppository, paste, tincture, electuary etc.
Feature of the present invention is as follows:
1, in this formula, contain the key component that affects eyes: macular pigment luteole and lutein, antioxidant and vitamin A.Unique pigment luteole at macular area center and spread all over amphiblestroid lutein, in Liang Zhong ocular tissue, to supplement be unique effectively means of Control and prevention macular degeneration at present to most important pigment simultaneously; Be aided with antioxidant and vitamin A simultaneously, eliminate the injury of radical pair ocular tissue, elimination kopiopia, vision protection are had to positive effect.
2, this formula is not only also of value to human body skin health for eye health protection.Luteole and lutein are not only macular pigment and are also had antioxidation, and the antioxidant acting in conjunction of wanting with body weight for humans such as vitamin C, vitamin E, zinc has a very important effect to human body is anti-oxidant; Lutein and luteole specificity absorb the characteristic of blue light, are of value to protection skin and avoid blue light injury.
3, have a good application prospect.That eye of the present invention nutrient formulation has is anti-oxidant, alleviate kopiopia, vision protection, effect that senile macular degeneration and cataract are had prevention and slowed down the pace, likely becomes food, health food, medicine, therefore has a good application prospect.
The specific embodiment
Embodiment 1
According to this formula rate, in every 100 grams of nutrients, contain: every 100 grams contain: luteole: 3 grams; Lutein: 3 grams, vitamin C: 30 grams, vitamin E: 15 grams, vitamin A: 0.04 gram, zinc gluconate: 30 grams, 33.96 grams of soybean oils.Be prepared into soft capsule, 0.5 gram every of capsule, takes 1 every day.
1 test method
1.1 test grouping 40 routine experimenters adopt random double-blind method to be divided into test-meal group and placebo group, every group of each 20 people, 35 ~ 65 years old age.Test-meal group man 12 people, female 8 people, 46.3 ± 15.1 years old age; Control group man 10 people, female 10 people, 48.2 ± 16.3 years old age.The factors such as age, sex, eyesight have comparativity, between test employing self cross-reference and group, contrast.
1.2 test-meal method test-meal groups are taken this patent formula soft capsule, and control group is taken placebo, are every day 1 time, and each 1, Time of Administration is 30 days.
1.3 observation index indices are each mensuration 1 time in the time of test-meal on-test and end.
Efficiency index: detailed medical history-taking, eye subjective symptoms: swollen, the ophthalmodynia of eye, photophobia, blurred vision, eye are dry and astringent etc.Add up integrated value by symptom weight (3 points of severes, 2 points of moderates, 1 point of light disease) in test-meal front and back, and improve situation (each symptom is improved 1 and is divided into effectively, and improvement 2 is divided into effective), calculating symptom improvement rate with regard to its cardinal symptom.Ophthalmology routine inspection: external eyes, eyeground.Visuognosis persistence test: the photopic vision time is called duration of photopic vision to the percentage of fixation time, minute is 3min, measures and averages for 2 times.Examination of distant vision: use c chart to check.
1.4 data processings and result decision data are processed by the stata6.0 of statistical software computational analysis data.Own control data adopts paired t-test, two groups of means relatively adopt t check in groups, and the latter need to carry out homogeneity test of variance, and Non-Gaussian Distribution or heterogeneity of variance analysis data are carried out to suitable variable conversion, after meeting normal state homogeneity of variance, with conversion data carry out t check; If translation data still can not meet the requirement of normal state homogeneity of variance, use t ' check or rank test instead; Too large to the coefficient of variation, as the data of CV>50%, application rank test.Effect index adopts X2 check to judge P value.
2 results
The comparison (X ± s, %) that before and after table one test-meal, duration of photopic vision changes
| Group | Number of cases | Before test-meal | After test-meal | Increase rate |
| Test-meal group | 20 | 55.32±8.12 | 73.28±10.03 | 17.96 |
| Control group | 20 | 58.63±10.07 | 59.93±10.59 | 1.30 |
Note: own control P<0.01 before and after test-meal; Between group, contrast P<0.01
Two groups of comparisons (X ± s, %) that distant vision changes before and after table two test-meal
Note: before and after test-meal, self compares P<0.05; Between group, contrast P<0.05
Table three symptom integral statistics (X ± s, %)
| Grouping | Number of cases | Before test-meal | After test-meal |
| Test-meal group | 20 | 7.18±2.09 | 4.08±2.12 |
| Control group | 20 | 7.15±1.93 | 5.96±2.31 |
Note: before and after test-meal, self compares P<0.01; Between group, contrast P<0.05
From above result can be seen the nutrient formulation of test-meal this patent, relatively or between test-meal group and control group group relatively, symptom is improved efficient or symptom total mark difference all conspicuousness (p<0.05) to test-meal group self; Duration of photopic vision difference has conspicuousness (p<0.05), and average duration of photopic vision raising is more than or equal to 10%.The not obvious reduction of eyesight improving rate, therefore can judge that this patent formula has the effect that contributes to asthenopia releasing function simultaneously.
Embodiment 2
According to this formula rate, in every 100 grams of nutrients, contain: every 100 grams contain: luteole: 7.5 grams; Lutein: 7.5 grams, vitamin C: 10 grams, vitamin E: 5 grams, vitamin A: 0.4 gram, zinc citrate: 60 grams, 9.6 grams of soybean oils.Be prepared into soft capsule, 0.5 gram every of capsule, takes 1 every day.
The testing result of nutrient alleviating asthenopia is identical with embodiment 1.
Embodiment 3
According to this formula rate, in every 100 grams of nutrients, contain: every 100 grams contain: luteole: 2 grams; Lutein: 2 grams, vitamin C: 5 grams, vitamin E: 1 gram, vitamin A: 0.2 gram, zinc gluconate: 30 grams, 59.8 grams of soybean oils.Be prepared into soft capsule, 0.5 gram every of capsule, takes 2 every day.
The testing result of nutrient alleviating asthenopia is identical with embodiment 1.
Claims (7)
1. a nutrients formula, in every 100 grams of nutrients formulas, the amount of active ingredient is: luteole: 0.15 ~ 7.5 gram; Lutein: 0.15 ~ 7.5 gram, vitamin C: 1 ~ 30 gram, vitamin E: 0.1 ~ 15 gram, vitamin A: 0.02 ~ 0.4 gram, zinc: 0.15 ~ 10 gram.
2. according to nutrients formula claimed in claim 1, it is characterized in that: the surplus in nutrients formula except active ingredient is carrier or auxiliary material.
3. according to the nutrients formula described in claim 1 or 2, it is characterized in that: described zinc is the zinc that is added into formula with zinc gluconate, zinc citrate or other zinc compound forms, and addition is in zinc element.
4. according to nutrients formula claimed in claim 2, it is characterized in that: described carrier or auxiliary material are acceptable carrier or auxiliary material on food or materia medica, nutrients formula is made different formulations according to the carrier or the auxiliary material that add.
5. the application of nutrients formula in food or the medicine of preparing alleviating asthenopia described in a claim 1-4 any one.
6. according to application claimed in claim 5, it is characterized in that: nutrients formula is made different formulations according to the carrier or the auxiliary material that add, and carrier or auxiliary material are acceptable carrier or auxiliary material on food or materia medica.
7. according to application claimed in claim 5, it is characterized in that: described nutrients formula is eyes nutrient, its have anti-oxidant, alleviate kopiopia, vision protection effect, the effect that senile macular degeneration and cataract are had prevention and slowed down the pace.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460781.3A CN103798808A (en) | 2012-11-15 | 2012-11-15 | Nutrient formula and application thereof to food or medicine for reliving asthenopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210460781.3A CN103798808A (en) | 2012-11-15 | 2012-11-15 | Nutrient formula and application thereof to food or medicine for reliving asthenopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103798808A true CN103798808A (en) | 2014-05-21 |
Family
ID=50696579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210460781.3A Pending CN103798808A (en) | 2012-11-15 | 2012-11-15 | Nutrient formula and application thereof to food or medicine for reliving asthenopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103798808A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105011154A (en) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | Composition for relieving asthenopia of the adolescent and promoting memory and preparation method of the composition for relieving asthenopia of the adolescent and promoting memory |
| CN106072545A (en) * | 2016-06-27 | 2016-11-09 | 北京康倍多生物科技有限公司 | The asthenopic xanthophyll chewable tablet of a kind of alleviation and preparation method |
| CN106420816A (en) * | 2016-09-28 | 2017-02-22 | 北京瑞济善健康科技有限公司 | Compound lutein solid preparation for relieving asthenopia and improving vision function and preparation method thereof |
| CN107156816A (en) * | 2017-05-22 | 2017-09-15 | 深圳泰乐德营养与健康有限公司 | A kind of health food suitable for early diabetes crowd and metabolic syndrome crowd |
| CN113439850A (en) * | 2021-06-20 | 2021-09-28 | 黑龙江冰泉多多保健食品有限责任公司 | Antioxidant soybean protein powder and preparation method thereof |
| CN113475714A (en) * | 2021-07-19 | 2021-10-08 | 汤臣倍健股份有限公司 | Cowberry leaf flavin soft capsule and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481804A (en) * | 2002-12-17 | 2004-03-17 | 无锡杰西医药科技有限公司 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
| WO2005117982A1 (en) * | 2004-05-18 | 2005-12-15 | Zeavision Llc | Ocular formulations with neuroprotectants to reduce alzheimer and neurotoxic risks created by large zinc dosages |
| WO2007046083A2 (en) * | 2005-10-16 | 2007-04-26 | Lycored Ltd. | Compositions for treatment of eye diseases |
| CN101583351A (en) * | 2006-12-15 | 2009-11-18 | 诺瓦提斯公司 | Nutritional supplement composition for treatment of ocular diseases |
| CN101999477A (en) * | 2010-11-24 | 2011-04-06 | 刘道鸣 | Eyesight-protecting edible oil |
-
2012
- 2012-11-15 CN CN201210460781.3A patent/CN103798808A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481804A (en) * | 2002-12-17 | 2004-03-17 | 无锡杰西医药科技有限公司 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
| WO2005117982A1 (en) * | 2004-05-18 | 2005-12-15 | Zeavision Llc | Ocular formulations with neuroprotectants to reduce alzheimer and neurotoxic risks created by large zinc dosages |
| WO2007046083A2 (en) * | 2005-10-16 | 2007-04-26 | Lycored Ltd. | Compositions for treatment of eye diseases |
| CN101583351A (en) * | 2006-12-15 | 2009-11-18 | 诺瓦提斯公司 | Nutritional supplement composition for treatment of ocular diseases |
| CN101999477A (en) * | 2010-11-24 | 2011-04-06 | 刘道鸣 | Eyesight-protecting edible oil |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105011154A (en) * | 2015-06-19 | 2015-11-04 | 北京元莱健康管理有限公司 | Composition for relieving asthenopia of the adolescent and promoting memory and preparation method of the composition for relieving asthenopia of the adolescent and promoting memory |
| CN106072545A (en) * | 2016-06-27 | 2016-11-09 | 北京康倍多生物科技有限公司 | The asthenopic xanthophyll chewable tablet of a kind of alleviation and preparation method |
| CN106420816A (en) * | 2016-09-28 | 2017-02-22 | 北京瑞济善健康科技有限公司 | Compound lutein solid preparation for relieving asthenopia and improving vision function and preparation method thereof |
| CN107156816A (en) * | 2017-05-22 | 2017-09-15 | 深圳泰乐德营养与健康有限公司 | A kind of health food suitable for early diabetes crowd and metabolic syndrome crowd |
| CN107156816B (en) * | 2017-05-22 | 2021-07-06 | 深圳奥萨制药有限公司 | Health food suitable for people with early diabetes and metabolic syndrome |
| CN113439850A (en) * | 2021-06-20 | 2021-09-28 | 黑龙江冰泉多多保健食品有限责任公司 | Antioxidant soybean protein powder and preparation method thereof |
| CN113475714A (en) * | 2021-07-19 | 2021-10-08 | 汤臣倍健股份有限公司 | Cowberry leaf flavin soft capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106236739B (en) | Contain lutein/lutein ester composition and its application | |
| CN101595977B (en) | Formula food beneficial to eye health and application thereof | |
| CN101856118A (en) | Health-care food for relieving asthenopia and preparation method thereof | |
| US20090297625A1 (en) | Agent for treating eye diseases | |
| CN102763847B (en) | Health-care food with function of relieving visual fatigue and preparation method thereof | |
| CN103798808A (en) | Nutrient formula and application thereof to food or medicine for reliving asthenopia | |
| CN102742656B (en) | Milky tea relieving asthenopia and preparation method thereof | |
| CN101199526A (en) | Improving eyesight guard inspect health care preparation and preparing method thereof | |
| CN104435763B (en) | A kind of medicine for treating illness in eye | |
| CN105878573A (en) | Composition for relieving visual fatigue | |
| CN101953470A (en) | Health food capable of alleviating asthenopia and preparation method thereof | |
| CN103566049A (en) | Composition for improving density of macular pigment in eyes and preventing or treating age-related macular degeneration | |
| CN107951955A (en) | A kind of compound for alleviating asthenopia | |
| CN104474018A (en) | Health-care soft capsule for relieving asthenopia | |
| CN107691854A (en) | Pet eye illness cream and preparation method thereof | |
| CN103316032B (en) | Compositions containing hydroxytyrosol and application thereof | |
| CN106617055A (en) | Eye-protecting healthcare food for relieving degenerative eye diseases and preparation method thereof | |
| CN101416741A (en) | Health-care food for relieving visual fatigue | |
| CN106692187A (en) | Composition for improving visuognosis persistence and protecting eye health | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN109010790A (en) | A kind of composition and its application for improving eye strain | |
| CN113826894A (en) | Capsule for relieving visual fatigue and preparation method thereof | |
| JP2018188438A (en) | Composition for prevention, improvement or treatment of posterior eye diseases | |
| CN1973873A (en) | Eye health food capsule | |
| CN103446475A (en) | Eye aging-resisting health product and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140521 |